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ABSTRACT
Objective: To discern how the public in four countries,
each with unique health systems and cultures, feels
about efforts to restrain healthcare costs by limiting
the use of high-cost prescription drugs and medical/
surgical treatments.
Design: Cross-sectional survey.
Setting: Adult populations in Germany, Italy, the UK
and the USA.
Participants: 2517 adults in the four countries. A
questionnaire survey conducted by telephone (landline
and cell) with randomly selected adults in each of the
four countries.
Main outcome measures: Support for different
rationales for not providing/paying for high-cost
prescription drugs/medical or surgical treatments,
measured in the aggregate and using four case examples
derived from actual decisions. Measures of public
attitudes about speciﬁc policies involving comparative
effectiveness and cost-beneﬁt decision making.
Results: The survey ﬁnds support among publics in
four countries for decisions that limit the use of high-
cost prescription drugs/treatments when some other
drug/treatment is available that works equally well but
costs less. The survey ﬁnds little public support, either
in individual case examples or when asked in the
aggregate, for decisions in which prescription drugs/
treatments are denied on the basis of cost or various
deﬁnitions of beneﬁts. The main results are based on
majorities of the public in each country supporting or
opposing each measure.
Conclusions: The survey ﬁndings indicate that the
public distinguishes in practice between the concepts
of comparative effectiveness and cost-effectiveness
analysis. This suggests that public authorities engaged
in decision-making activities will ﬁnd much more
public support if they are dealing with the ﬁrst type of
decision than with the second.
The rising cost of healthcare is seen as
a serious concern in many industrialised
countries. Increasingly, the focus by national
governments for restraining these costs has
been to have independent agencies assess
whether the beneﬁts of speciﬁc high-cost
prescription drugs, diagnostic tests and
medical or surgical treatments justify their
cost. If this is not seen to be the case, these
agencies may recommend that payors or
government health systems not pay for or
provide these medical care interventions.
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ARTICLE SUMMARY
Article focus
- Despite increasing concerns among government
ofﬁcials about high healthcare spending, a survey
of the public in four countries ﬁnds little support
for decisions that limit use of high-cost prescrip-
tion drugs and treatments.
- The results provide insights for policy-makers,
indicating that the public distinguishes in practice
between the concepts of comparative effective-
ness and cost-beneﬁt analysis. They will gener-
ally support decisions related to the ﬁrst but not
the second.
Key messages
- Government agencies dealing with cost-control
issues should highlight those decisions not to
pay for or provide the more expensive drug or
treatment when two prescription drugs or
treatments have the same outcome but one is
more expensive than the other.
- Policy-makers need to be aware that when they
discuss limiting the availability of high-cost
prescription drugs or treatments based on the
assessment of broader beneﬁts, they may face
considerable public controversy.
Strengths and limitations of this study
- This is the only multi-country study of attitudes
on this subject. It is unique in that it includes
responses for four actual cases where govern-
ments made decisions about what should be paid
for or provided.
- For general public respondents, these are
complex issues that may be difﬁcult to under-
stand, and some responses might differ if
respondents were aware of other factors.
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Open Access ResearchIn Germany, the Institute for Quality and Efﬁciency in
Healthcare (IQWiGdInstitut fu ¨r Qualita ¨t und Wirt-
schaftlichkeit im Gesundheitswesen) has been respon-
sible for health technology assessments across a range of
pharmaceuticals and therapeutics since 2004.
1e3 In Italy,
the Italian Medicines Agency (AIFAdAgenzia Italiana
del Farmaco) conducts health technology assessments,
evaluating the clinical beneﬁts of new products and, in
conjunction with the Pricing and Reimbursement
Committee (CPRdComitato Prezzi e Reimborso),
judges cost-effectiveness.
4 In the UK, the National
Health Service has since 1999 relied on the National
Institute for Clinical Excellence to generate cost-effec-
tiveness assessments and determine whether new treat-
ments offer enough value to justify adding their costs to
the health system.
35In the USA, 2010 saw the advent of
a new comparative effectiveness agency, the Patient-
Centered Outcomes Research Institute. However, the
new US agency was established with an explicit ban on
the use of any cost-effectiveness analysis in payment or
provision decisions, in notable contrast to its more
empowered European counterparts.
67
As this approach to restraining health costs grows, the
question is raised about how accepting the public in
these various countries will be to these types of decisions.
Healthcare is a visible and popular issue. From one
perspective, it might be expected that the public would
support these approaches to containing costs and
keeping health systems more affordable. On the other
hand, they may see these government- or insurance-
sponsored decisions as interfering in important indi-
vidual physician and patient choices and thus oppose
them.
To date, there has not been an assessment of public
attitudes across various countries on this question. A
prior survey that looked at part of this overall issue found
that the US public was resistant to the use of comparative
effectiveness research results for patient care expendi-
ture decisions. The public was supportive of its use for
general information, but not decision-making purposes.
8
An earlier study found that a majority of the German
public favoured government not limiting spending for
health services, opposed limiting beneﬁts to a core of
essential beneﬁts and thought treatment decisions
should be made by doctors.
9 A study in Italy found that
when given a single case example, there was consider-
able public resistance to rationing or priority setting.
10
In a recent study aimed at examining the German
public’s attitudes towards proposed criteria for priori-
tising health services, little evidence of support was
found for using age as a criterion.
11
In this article, we seek to provide an answer about
public acceptance of these types of decisions by looking
at the ﬁndings of a recent four-country survey. The data
reported from Germany, Italy, the UK and the USA offer
results about public attitudes towards these key ques-
tions. It also provides the public response in each
country to four case examples of actual decisions in
which the high cost of a medical intervention was not
thought by payors or governments to be justiﬁed by its
overall beneﬁts.
METHODS
The data are derived from a four-country survey by the
Harvard School of Public Health and the Alliance for
Aging Research. Fieldwork was conducted via telephone
(landline and cell) with nationally representative
random samples of adults aged 18 years and older in
four countries by SSRS/ICR, an independent research
company. Interview dates, sample sizes and margins of
error are shown below. The sample sizes are typical of
public opinion surveys.
Non-response in telephone surveys produces some
known biases in survey-derived estimates because partici-
pation tends to vary for different subgroups of the popu-
lation. To compensate for these known biases, a post-
stratiﬁcation weighting design was used to weight all
collected interviews to represent each country’s
adult population. Weighting targets included telephone
status (landline, cell) and various individual demographics:
race/ethnicity (USA only), age, gender, education
and region. Other techniques, such as callbacks staggered
o v e rt i m e so fd a y sa n dd a y so fw e e k sa n ds y s t e m a t i c
respondent selection within households, are used to help
ensure that the sample in each country is representative.
After weighting, the sample for each country reﬂects
the demographic composition of the adult population of
that country. The results for each country are general-
isable to the adult population of that country.
The survey instrument comprised a range of questions
relating to support for different rationales for not
providing/paying for high-cost prescription drugs/
medical or surgical treatments, measured in the aggre-
gate and using four-case examples derived from actual
decisions and attitudes about speciﬁc policies involving
comparative effectiveness and cost-beneﬁt decision
making. The question wordings are shown in more detail
on the three tables.
The survey included four case examples, derived from
comparative effectiveness decisions that had actually
been made in one or another of the countries.
Respondents were read a paragraph about the decision,
Interview dates
Total
interviews
Margin of error
(percentage points)
Germany 30 June 2011 to
19 July 2011
500 65.4
Italy 30 June 2011 to
19 July 2011
500 65.4
UK 30 June 2011 to
19 July 2011
500 65.4
USA 28 June 2011 to
24 July 2011
1017 63.9
2 Blendon RJ, Benson JM, Botta MD, et al. BMJ Open 2012;2:e001087. doi:10.1136/bmjopen-2012-001087
Four-country survey of attitudes towards limiting use of high-cost interventionswithout mention of the country where the decision was
made or the name of the prescription drug or diagnostic
test involved and then asked whether they approved or
disapproved of the decision. The content of the case
examples, whose wordings appear in table 2, were
derived from journal or newspaper accounts or the
actual decision. The drug/test, disease and country for
the four decisions were (1) Avastin/bowel cancer/UK,
12
(2) Avastin/Lucentis/wet age-related macular degener-
ation (wet AMD)/Italy,
13 (3) b interferon/multiple
sclerosis/UK
14 and (4) positron emission tomography
(PET scans)/head and neck tumours/Germany.
15
Many of the questions in the survey were asked of split
samples, where one half was asked about prescription
drugs and the other half about medical or surgical
treatments. Because the responses of the two half
samples were similar, the data for the two forms were
combined for clarity of presentation and to increase
statistical power. In the UK and Italy, questions were
asked about ‘the national health service providing.’. In
Germany and the USA, questions were asked about ‘the
government or health insurance plans paying for.’.
Data analysis comprises descriptive statistics to ascer-
tain public attitudes on each of the measures. Percent-
ages and CIs (at the 95% conﬁdence level) are shown for
the responses to each survey item in each country. The
base for calculating percentages included all respon-
dents who were asked the question, so there are no
missing data. ‘Don’t know/refused’ responses are
included in the base but are not shown in the tables
unless they are 10% or greater for the question in one or
more countries.
The Institutional Review Board at the Harvard School
of Public Health ruled that this study is not human
Table 1 Public attitudes in four countries about comparative effectiveness decision making and patient access (in per cent)
Germany (n[500),
% (95% CI)
Italy (n[500),
% (95% CI)
UK (n[500),
% (95% CI)
USA (n[1017),
% (95% CI)
In (your country) the (government or health insurance plans withhold/national health service withholds) high-cost (prescription
drugs/medical or surgical treatments) from people who might beneﬁt in order to save money.
Very often 15 (11 to 19) 19 (15 to 24) 11 (7 to 14) 29 (26 to 33)
Somewhat often 43 (38 to 48) 36 (31 to 41) 28 (23 to 33) 38 (34 to 41)
Not too often 30 (25 to 35) 25 (20 to 29) 39 (33 to 44) 20 (17 to 23)
Not at all 4 (2 to 7) 9 (6 to 12) 19 (15 to 23) 7 (5 to 9)
Don’t know/refused 7 (4 to 10) 11 (8 to 14) 4 (1 to 6) 6 (4 to 8)
Paying for/providing approved (prescription drugs/medical or surgical treatments) regardless of cost (respondents were asked
to choose between two statements:)
The (government or health insurance
plans should pay for/national health
service should provide) any
(prescription drug/medical or surgical
treatment) that has been approved
as being safe and effective for saving
lives or improving people’s health,
regardless of what it costs
61 (56 to 66) 77 (72 to 81) 60 (55 to 65) 59 (55 to 62)
There are so many new expensive
prescription drugs and medical or
surgical treatments that it is too
expensive for (government or health
insurance plans to pay for/the
national health service to provide) all
of them
35 (29 to 40) 20 (16 to 24) 38 (33 to 43) 35 (31 to 39)
The (government or your health insurance plan paying for/national health service providing) more expensive (prescription drug/
medical or surgical treatment) recommended by your doctor even if it has not been shown to work better than less expensive
(drugs/treatments)
Favour paying for/providing (oppose
comparative effectiveness)
43 (37 to 48) 21 (17 to 25) 29 (24 to 34) 33 (29 to 37)
Oppose paying for/providing (favour
comparative effectiveness)
49 (44 to 54) 70 (65 to 75) 69 (64 to 74) 64 (61 to 68)
Some (prescription drugs/medical or surgical treatments) that have been shown to be safe and effective should not be (paid for
by the government or health insurance plans/provided by the national health service) because their high cost is not felt to be
justiﬁed by the amount of beneﬁt they provide
Favour not paying for/providing 32 (27 to 37) 31 (26 to 36) 34 (28 to 39) 31 (27 to 34)
Oppose not paying for/providing 59 (54 to 65) 61 (56 to 66) 63 (58 to 68) 62 (59 to 66)
Source: Harvard School of Public Health/Alliance for Aging Research Survey, 2011.
‘Don’t know/refused’ responses not shown unless they are 10% or greater for the question in one or more countries.
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2010).
RESULTS
Across the four countries, many people believe that high-
cost drugs and treatments are already often being with-
held. Majorities of the public in Germany (58%), Italy
(55%) and the USA (67%) believe that in their country,
high-cost prescription drugs/medical or surgical treat-
ments are very or somewhat often withheld from some
people who might beneﬁt from them in order to save
money. This belief is not shared by a majority in the UK,
where 39% believe drugs/treatments are often withheld
(table 1).
Majorities in all four countries believe that any
prescription drug/medical or surgical treatment that has
been approved as safe and effective for saving lives or
improving people’s health should be paid for or
provided, regardless of cost. Paying for or providing
these drugs/treatments is favoured by about three-
fourths of the public in Italy (77%) and about six in 10
in Germany (61%), the UK (60%) and the USA (59%).
A majority in Italy (70%), the UK (69%) and the USA
(64%) oppose the government, health insurance plans
or the national health service paying for or providing
a prescription drug/medical or surgical treatment
recommended by their doctor if it has not been shown to
work better than less expensive ones. This view is shared
by a plurality (49%) in Germany. This is often referred to
as comparative effectiveness research.
However, the public does not support decisions in
which prescription drugs/medical or surgical treatments
are denied on the basis of cost or various deﬁnitions of
beneﬁts. The public was asked whether some prescrip-
tion drugs/medical or surgical treatments that have
been shown to be safe and effective should not be paid
for or provided because of their high cost is not felt to be
justiﬁed by the amount of beneﬁt they provide. About six
Table 2 Public attitudes in four countries about actual coverage decisions (in per cent)
Germany (n[250),
% (95% CI)
Italy (n[250),
% (95% CI)
UK (n[250),
% (95% CI)
USA (n[509),
% (95% CI)
In one country, the national government decided against (paying for/providing) a new drug for treating an advanced form of
cancer. On average, the drug costs ($35000/£21000/V25000) per patient. The drug does not cure the disease, but studies
suggest that using the drug can add, on average, about 6 months to a patient’s life. Some patients would gain only a short
period, while others could gain a lot more time. If this decision not to (pay for/provide) this drug were made in (your country),
would you approve or disapprove of the decision?
Approve 36 (28 to 43) 39 (32 to 47) 24 (17 to 30) 37 (32 to 43)
Disapprove 60 (53 to 68) 51 (44 to 59) 76 (69 to 82) 59 (54 to 65)
In one country, two drugs were available to treat a debilitating condition in the elderly. One of the drugs costs about 100 times
as much as the other. The more expensive one has been tested and shown to be effective for people with this condition. The
less expensive one has not been tested in research studies for treating this illness. However, many physicians who specialise in
the condition use the lower cost drug because they believe it is safe and effective for their patients. This is often referred to as
using an off-label drug. The government in that country decided to pay for/provide/pay only the less expensive drug even
though it had not been tested for this illness. If this decision only to (pay for/provide) the less expensive drug that had not been
tested for this illness were made in (your country), would you approve or disapprove of the decision?
Approve 24 (18 to 31) 25 (18 to 31) 20 (14 to 26) 26 (21 to 31)
Disapprove 70 (63 to 78) 71 (64 to 80) 80 (74 to 86) 71 (66 to 76)
A new drug is available for a serious debilitating disease. It does not cure the disease, but it can provide relief for the symptoms
of the disease. In one country, the national government decided to (pay for/provide) this drug only for a limited number of
patients because of the drug’s high cost of ($15000/£9000/V11000) a year. The drug is reserved for those patients who are
most likely to see signiﬁcant health beneﬁts. Some people have objected to the decision because they argue that other patients
might also beneﬁt from the drug. If this decision to (pay for/provide) this drug only for a limited number of patients were made in
(your country), would you approve or disapprove of the decision?
Approve 28 (21 to 35) 26 (20 to 32) 27 (20 to 34) 28 (22 to 33)
Disapprove 66 (58 to 73) 71 (64 to 77) 72 (65 to 79) 69 (64 to 75)
In one country, the national government decided against (paying for/providing) the use of an imaging technology for diagnosing
certain types of cancers. The technology is more expensive than alternative methods, costing over ($2000/£1200/V1400) per
use. After conducting an evaluation, a government organisation concluded that there was not enough scientiﬁc evidence to
recommend using the technology for these other types of cancer. Other countries, however, actively use this technology for
multiple types of cancer because many doctors believe it provides the best most detailed view of these other types of tumours.
The evaluation organisation argued that existing studies have not conclusively proven that the technology has advantages over
alternative methods and therefore should not be (paid for/provided). If this decision not to (pay for/provide) this technology to
help diagnose these other types of cancer were made in (your country), would you approve or disapprove of the decision?
Approve 26 (19 to 32) 53 (46 to 60) 18 (13 to 24) 34 (28 to 39)
Disapprove 67 (60 to 75) 39 (32 to 47) 78 (71 to 84) 63 (57 to 68)
Source: Harvard School of Public Health/Alliance for Aging Research Survey, 2011.
‘Don’t know/refused’ responses not shown.
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and 62% in the USAdwere opposed.
When it comes to case examples of speciﬁc decisions
involving cost and beneﬁts that have been made,
majorities in all four countries disapproved of three of
the four decisions presented in the survey. In a fourth
case example, a decision not to pay for or provide an
imaging technology for diagnosing certain types of
cancer, majorities in three of the countries disapproved,
while a majority in Italy approved (table 2).
The survey asked people whether they would favour or
oppose their country having a government decision-
making body that recommends whether government
programmes should pay for or provide prescription
drugs/medical or surgical treatments if they think they
cost too much. Public opinion in the four countries
differs. Majorities in Germany (69%) and Italy (71%)
favour having such an agency. A majority (54%) in the
USA oppose having such an agency, while 43% favour
having one. The public in the UK is about evenly
divided, with 46% in favour and 48% opposed (table 3).
In spite of these differences in approval for a govern-
ment decision-making body, majorities in all four coun-
tries believe that such an agency would provide doctors
with useful scientiﬁc information about what works for
patients with a given disease or medical condition.
With regard to governmental decision-making in
healthcare, majorities in Italy and the UK say that they
trust their national government to make the right
healthcare decisions, while majorities in Germany and
the USA say they do not.
DISCUSSION
The survey ﬁndings indicate that the public distin-
guishes in practice between the concepts of comparative
effectiveness and cost-beneﬁt analysis. When two
prescription drugs or treatments have the same outcome
but one is more expensive than the other, the public
supports policies that would not pay for or provide the
more expensive one in the absence of evidence that it
would work better than the less expensive alternative.
On the other hand, the survey found little public
support, either in individual case examples or when
asked in the aggregate, for the establishment of broader
beneﬁts as a criterion for whether or not a drug or
treatment should be paid for or provided. If the
evidence shows that a drug or treatment beneﬁts some
patients for some period of time, the public is reluctant
to have these medical interventions not paid for or
provided.
Taken together, this suggests that across the four
countries, public authorities engaged in decision-making
activities will ﬁnd much more public support if they are
dealing with the ﬁrst type of decision than with the
second. In addition, public ofﬁcials may face public
resistance for decision-making about whether to pay for
or provide high-cost medical interventions because
a large proportion of the public believes that some high-
cost prescription drugs and treatments are already being
withheld.
This study has two main limitations. First, these types
of policy-making decisions may be difﬁcult for the
general public to understand fully. Second, although
respondents were told that these types of decisions were
being made as a way of limiting future healthcare costs,
they might have answered differently had they been told
that these decisions might lower their taxes or health
insurance premiums in the future, if that were the case.
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